AR027714A1 - USE OF METAL SALTS TO STABILIZE TAXANOS COMPOSITIONS. - Google Patents

USE OF METAL SALTS TO STABILIZE TAXANOS COMPOSITIONS.

Info

Publication number
AR027714A1
AR027714A1 ARP010101394A ARP010101394A AR027714A1 AR 027714 A1 AR027714 A1 AR 027714A1 AR P010101394 A ARP010101394 A AR P010101394A AR P010101394 A ARP010101394 A AR P010101394A AR 027714 A1 AR027714 A1 AR 027714A1
Authority
AR
Argentina
Prior art keywords
acid
acids
compositions
metal salt
vehicle
Prior art date
Application number
ARP010101394A
Other languages
Spanish (es)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of AR027714A1 publication Critical patent/AR027714A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se describen composiciones que contienen un taxano, un vehículo y una sal metálica de un ácido. Los ácidos preferidos incluyen aminoácidos, ácido ascorbico, ácidos grasos tal como ácidos palmíticos, alfa y beta hidroxiácidos tal como ácido cítrico y ácido gluconico, ácido fluorhídrico, ácido clorhídrico, ácidobromhídrico, ácido iodhídrico, ácido benzoico, ácido sulfurico, ácido hidroximetilsulfínico y ácido sulfonico. También se describen métodos para estabilizarcomposiciones de taxano/vehículo y reducir la degradacion de taxanos por ejemplo, durante el almacenamiento. Los métodos comprenden la inclusion de la salmetálica en la composicion de taxano o el pretratamiento del vehículo con la sal metálica, optativamente en combinacion con otros pretratamientos.Compositions containing a taxane, a vehicle and a metal salt of an acid are described. Preferred acids include amino acids, ascorbic acid, fatty acids such as palmitic acids, alpha and beta hydroxy acids such as citric acid and gluconic acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, iodhydric acid, benzoic acid, sulfuric acid, hydroxymethylsulfinic acid and sulfonic acid . Methods for stabilizing taxane / vehicle compositions and reducing the degradation of taxanes for example during storage are also described. The methods include the inclusion of the metal salt in the taxane composition or the pretreatment of the vehicle with the metal salt, optionally in combination with other pretreatments.

ARP010101394A 2000-03-24 2001-03-23 USE OF METAL SALTS TO STABILIZE TAXANOS COMPOSITIONS. AR027714A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19180200P 2000-03-24 2000-03-24

Publications (1)

Publication Number Publication Date
AR027714A1 true AR027714A1 (en) 2003-04-09

Family

ID=22706985

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010101395A AR027715A1 (en) 2000-03-24 2001-03-23 COMPOSITIONS BASED ON TAXANS AND METHODS OF USE OF THE SAME
ARP010101394A AR027714A1 (en) 2000-03-24 2001-03-23 USE OF METAL SALTS TO STABILIZE TAXANOS COMPOSITIONS.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010101395A AR027715A1 (en) 2000-03-24 2001-03-23 COMPOSITIONS BASED ON TAXANS AND METHODS OF USE OF THE SAME

Country Status (7)

Country Link
EP (2) EP1315484A1 (en)
JP (2) JP2003528142A (en)
KR (2) KR20030019328A (en)
AR (2) AR027715A1 (en)
AU (2) AU2001247739A1 (en)
CA (2) CA2404370A1 (en)
WO (2) WO2001072299A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515187A (en) * 2001-11-26 2005-05-26 スーパージェン インコーポレイテッド Process for the preparation of pharmaceutical compositions using polyoxyethylated castor oil
CA2471572A1 (en) * 2001-12-28 2003-07-17 Ivax Research, Inc. Taxane based compositions and methods of use
KR100533458B1 (en) * 2002-07-20 2005-12-07 대화제약 주식회사 Composition for solubilization of paclitaxel and preparation method thereof
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US20090004166A1 (en) * 2004-08-03 2009-01-01 Simon Michael West Carrier For Enternal Administration
KR100866728B1 (en) * 2004-11-12 2008-11-03 주식회사종근당 The injection of tacrolimus
EP1690551A3 (en) 2005-02-10 2006-10-18 Sindan Pharma Srl Method of purifying a surfactant by ultrafiltration
WO2006084902A2 (en) * 2005-02-10 2006-08-17 Sindan Pharma Srl Method of purifying a surfactant by ultrafiltration
CA2611592A1 (en) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
EP2548581A3 (en) 2005-06-17 2013-02-20 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
DK3311805T3 (en) 2005-08-31 2020-04-14 Abraxis Bioscience Llc COMPOSITIONS CONTAINING VERY WATER-SOLUBLE PHARMACEUTICAL AND ANTIMICROBIAL AGENTS
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
BRPI0600194A (en) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A docetaxel-containing pharmaceutical compositions and a degradation inhibitor and process for obtaining same
ES2344674B1 (en) 2008-08-07 2011-06-29 Gp Pharm, S.A. INJECTABLE PHARMACEUTICAL COMPOSITION OF TAXANOS.
JO3434B1 (en) * 2009-07-31 2019-10-20 Millennium Pharm Inc Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
US8652511B2 (en) 2010-03-30 2014-02-18 Phosphagenics Limited Transdermal delivery patch
CN102970990A (en) 2010-05-03 2013-03-13 帝国制药美国公司 Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
RU2603833C2 (en) * 2010-11-08 2016-11-27 Кадила Фармасьютикалз Лимитед Pharmaceutical composition of taxoids
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
JO3685B1 (en) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
JP6360881B2 (en) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Combination of catalytic MTORC1 / 2 inhibitor and selective inhibitor of Aurora A kinase
JP6882321B2 (en) 2015-12-09 2021-06-02 フォスファージニクス リミテッド Pharmaceutical product
BR112019012946A2 (en) 2016-12-21 2019-11-26 Avecho Biotechnology Ltd process
CN110585189B (en) * 2019-09-05 2022-12-30 广东艾时代生物科技有限责任公司 Application of cephalomannine in preparation of medicines for treating malaria

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
KR19990075621A (en) * 1998-03-23 1999-10-15 임성주 Inclined Plate Culture Tank
CN1225262A (en) * 1998-12-09 1999-08-11 延边香料研究所 Anti cancer drug contg. taxals alcohol
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel

Also Published As

Publication number Publication date
WO2001072299A1 (en) 2001-10-04
AR027715A1 (en) 2003-04-09
AU2001247739A1 (en) 2001-10-08
EP1408956A1 (en) 2004-04-21
AU2001247726A1 (en) 2001-10-08
CA2404370A1 (en) 2001-10-04
JP2003528142A (en) 2003-09-24
CA2404374A1 (en) 2001-10-04
EP1315484A1 (en) 2003-06-04
KR20030019327A (en) 2003-03-06
KR20030019328A (en) 2003-03-06
JP2003528141A (en) 2003-09-24
WO2001072300A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
AR027714A1 (en) USE OF METAL SALTS TO STABILIZE TAXANOS COMPOSITIONS.
AR051404A1 (en) CLEANING COMPOSITIONS AND DISINFECTANTS
ES2085192B1 (en) DEPIGMENTING COSMETIC COMPOSITIONS BASED ON COFFEE ACID.
PE20010709A1 (en) METHODS AND SYSTEMS FOR THE TREATMENT OF ILL TISSUE WITH ANTIINFECTIVE COMPOSITIONS
SV2010003673A (en) NEW HETEROCICLIC COMPOUNDS AND USES OF THE SAME
PE20070437A1 (en) AQUEOUS FORMULATION hFSH
ES2132676T3 (en) PEROXYGEN COMPOSITIONS.
PE20090605A1 (en) COMPOSITIONS OF AMMONIA PHENYLALANINE-LIASA PROCARIOTICA AND METHODS OF TREATMENT OF CANCER USING COMPOSITIONS OF THE SAME
AR014877A1 (en) COMPOSITIONS AND METHODS TO INHIBIT THE PHOTO AGING OF THE SKIN
AR033059A1 (en) INSULIN PREPARED EXEMPT FROM ZINC AND POOR IN ZINC, WITH IMPROVED STABILITY.
PA8509801A1 (en) AZALIDA ANTIBIOTIC COMPOUNDS
AR052247A1 (en) A METHOD AND A COSMETIC COMPOSITION TO INHIBIT OR SIMULTANEOUSLY CONTROL THE TRANSPIRATION AND / OR EVIL ODOR AND IMPROVE OR CONTROL THE SKIN DARKNESS
ES2188031T3 (en) DETERGENT OF TOLERABLE HANDS BY SKIN, ESPECIALLY FOR ABRASIVE CLEANING OF HANDS.
BR0206469A (en) Injectable Depot Composition
AR037755A1 (en) AQUOUS COMPOSITIONS WITH METRONIDAZOL CONTENT
AR029737A1 (en) CONCENTRATES OF ANTI-FREEZERS BASED ON AMIDAS AND REFRIGERANT COMPOSITIONS THAT INCLUDE THEM, FOR THE PROTECTION OF MAGNESIUM AND MAGNESIUM ALLOYS
AR072685A1 (en) TOPICAL COMPOSITION FOR THE TREATMENT OF ACTINIC KERATOSIS
CO4920220A1 (en) COMPOSITIONS CONTAINING FLUOROETER COMPOUNDS AND METHODS TO INHIBIT THEIR DEGRADATION IN THE PRESENCE OF A LEWIS ACID
AR049587A1 (en) PHOSPHATED HYDROXYL COMPOUND, ITS USE AS HYDROTROPE AND CLEANING COMPOSITION CONTAINING THE PHOSPHATED COMPOUND
ATE404176T1 (en) STABILIZED LYOPHILIZED PREPARATIONS WITH TISSUE FACTOR INHIBITOR (TFPI) OR VARIANTS OF TISSUE FACTOR INHIBITOR
AR038985A1 (en) PARECOXIB SODICO CRISTALINO
ES2632933T3 (en) Enzyme cleaning composition and method of use
AR010178A1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING THE ACTIVE SUBSTANCE CILANSETRON, USE OF ADDITIVES AND PROCEDURE FOR THE PRODUCTION OF SUCH PREPARATIONS
CR7515A (en) VETERINARY COMPOSITION INJECTABLE FOR SMALL ANIMALS
AR050134A1 (en) METHODS TO EXTEND THE STORAGE DURATION AND REVITALIZE LIGHT WEIGHT BALLOONS FOR EMPLOYMENT IN CEMENT COMPOSITIONS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal